Glucose-stimulated Pancreatic Islet and Intestinal Blood Flow in Healthy Subjects and in Type 1 Diabetes (ISLET-PET)

Glucose-stimulated Pancreatic Islet and Intestinal Blood Flow in Healthy Subjects and in Type 1 Diabetes Using Positron Emission Tomography and Diffusion Weighted Imaging

Type 1 diabetes is the major type of diabetes in the young. The pathophysiology still needs clarification in order to reach feasible means of preventing the disease. This study aims in defining the differences in pancreatic and intestinal blood flow between subjects with and without type 1 diabetes and validating the methodology to achieve this. Earlier animal studies have demonstrated changes in pancreatic islet blood flow using microspheres. The aim of this study is to test and validate a method for the assessment of islet perfusion in humans using molecular imaging. The investigators hypothesize that glucose-stimulated pancreatic perfusion is enhanced specifically in islets in healthy subjects and that this increase is mostly suppressed in subjects with type 1 diabetes.

Positron emission tomography (PET) is a non-invasive imaging technique, which can be used to study flow and metabolism of different organs. Using radiowater ([15O]H2O) and PET, cellular perfusion can be measured directly and noninvasively. Recently, diffusion weighted magnetic resonance imaging (DWI) has also been applied as a complimentary method for the assessment to quantitate changes in pancreatic blood flow.

In the study 10 healthy subjects and 10 subjects with type 1 diabetes will be imaged on two separate days. Pancreatic and intestinal perfusion are first measured with [15O]H2O and combined PET/magnetic resonance imaging before and 5 and 15 minutes after intravenous glucose infusion. On the second day, PET imaging is replaced by dynamic DWI conducted in the same time schedule and with intravenous glucose stimulation.

Study Overview

• Status: Completed
• Conditions: Type 1 Diabetes

• Study Type: Observational
• Enrollment (Actual): 11

Contacts and Locations

Study Locations

• Finland
  • Turku, Finland, 20520
    • Turku PET Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 30 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Healthy subjects recruited via newspaper advertisements. Subjects with Type 1 diabetes recruited at the policlinics of endocrinology and internal medicine in the district of Turku University Hospital.

Description

Criteria for healthy subjects

Inclusion criteria

• Healthy as judged by history and examination
• Age 18-30 years
• Body mass index (BMI) 18 - 27 kg/m2
• Normal 2 h oral glucose tolerance test

Exclusion criteria

• Any chronic disease
• Pregnancy
• Blood pressure > 140/90 mmHg
• Smoking
• Presence of any ferromagnetic objects in the body
• Any other condition that could possibly create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of the study results

Criteria for subjects with type 1 diabetes (T1D)

Inclusion criteria

• T1D diagnosed at least 5 years ago
• Age 18-30 years
• BMI 18 - 30 kg/m2
• Good or moderate glycemic control with long-acting insulin analogue combined with injections of rapid-acting insulin
• Uncomplicated T1D or with minor microvascular complications

Exclusion criteria

• Any other condition or disease possibly affecting circulation, as evaluated by a physician
• Pregnancy
• Blood pressure > 140/90 mmHg
• Smoking
• Presence of any ferromagnetic objects in the body
• Any other condition that could possibly create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of the study results

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Healthy subjects
Type 1 diabetes

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pancreatic islet blood flow acquired with PET and DWI (ml ml-1 min-1)	healthy subjects and subjects with T1DM are studied once using imaging	within one study day
Intestinal blood flow acquired with PET and DWI (ml ml-1 min-1)	healthy subjects and subjects with T1DM are studied once using imaging	within one study day

Collaborators and Investigators

• Sponsor: Turku University Hospital
• Collaborators: Academy of Finland
• Investigators: Principal Investigator: Pirjo Nuutila, Prof., Turku PET Centre

Study record dates

Study Major Dates

• Study Start (Actual): September 10, 2015
• Primary Completion (Actual): May 1, 2021
• Study Completion (Actual): June 10, 2021

Study Registration Dates

• First Submitted: September 2, 2015
• First Submitted That Met QC Criteria: September 9, 2015
• First Posted (Estimate): September 11, 2015

Study Record Updates

• Last Update Posted (Actual): December 17, 2021
• Last Update Submitted That Met QC Criteria: December 16, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1
• Other Study ID Numbers: ISLET-PET